|
Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients
|
| Naser Aghamohammadzadeh *, Ali Tabrizi, Mitra Niafar, Farzad Najafipor |
|
|
|
Abstract: (9798 Views) |
Background: To evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes.
Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later.
Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy.
Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents. |
|
| Keywords: Type 2 Diabetes, Glutazone, Metformin, Glibenclamide |
|
|
Full-Text [PDF 53 kb]
(2473 Downloads)
|
Type of Study: Original Article |
Subject:
Infectious Diseases
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14
|
|
|
|
|
|
|
| Add your comments about this article |
|
|
|
